Regulation of p110δ PI 3-kinase gene expression

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Kok, Klaartje ^a,b   Nock, Gemma E ^a   Verrall, Elizabeth A G ^a   Mitchell, Michael P ^c   Hommes, Daan W ^d   Peppelenbosch, Maikel P ^b   Vanhaesebroeck, Bart ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P110DELTA; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, MOUSE; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; HISTONE; ISOENZYME; PIK3CB PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BINDING SITE; BONE MARROW CELL; CELL STIMULATION; CONTROLLED STUDY; EXON; FIBROBLAST; GENE CLUSTER; GENE EXPRESSION REGULATION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; RNA TRANSCRIPTION; START CODON; TRANSCRIPTION REGULATION; ANIMAL; CELL LINE; DNA METHYLATION; DNA SEQUENCE; GENETICS; LEUKOCYTE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; REPORTER GENE; RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 5' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; DNA METHYLATION; EXONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; HISTONES; HUMANS; ISOENZYMES; LEUKOCYTES; MICE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RNA STABILITY; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

EID: 65249157965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005145     Document Type: Article

References (94)

1. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, et al. (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602.
2. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22: 267-272.
3. Krugmann S, Hawkins PT, Pryer N, Braselmann S (1999) Characterizing the Interactions between the Two Subunits of the p101/p110gamma Phosphoinositide 3-Kinase and Their Role in the Activation of This Enzyme by Gbeta gamma Subunits. J Biol Chem 274: 17152-17158.
4. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, et al. (1997) The G[beta][gamma] Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101. Cell 89: 105-114.
5. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, et al. (2005) p84, a New G[beta][gamma]-Activated Regulatory Subunit of the Type IB Phosphoinositide 3-Kinase p110[gamma]. Current Biology 15: 566-570.
6. Voigt P, Dorner MB, Schaefer M (2006) Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 281: 9977-9986.
7. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, et al. (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 105: 8292-8297.
8. Jia S, Liu Z, Zhang S, Liu P, Zhang L, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
9. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, et al. (2008) Phosphoinositide 3-Kinase p110{beta} Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. Sci Signal 1: ra3.
10. Kok K, Geering B, Vanhaesebroeck B (2008) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci Accepted for publication.
11. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274: 10963-10968.
12. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 104: 7809-7814.
13. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, et al. (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94: 4330-4335.
14. Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13: 169-172.
15. Hu P, Mondino A, Skolnik EY, Schlessinger J (1993) Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol Cell Biol 13: 7677-7688.
16. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, et al. (1997) p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 272: 19236-19241.
17. Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, et al. (2007) Control of Axonal Growth and Regeneration of Sensory Neurons by the p110delta PI 3-Kinase. PLoS ONE 2: e869.
18. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, et al. (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63: 1667-1675.
19. Hirsch E, Wymann MP, Patrucco E, Tolosano E, Bulgarelli-Leva G, et al. (2000) Analysis of the murine phosphoinositide 3-kinase gamma gene. Gene 256: 69-81.
20. Barbier M, Attoub S, Calvez R, Laffargue M, Jarry A, et al. (2001) Tumour biology. Weakening link to colorectal cancer? Nature 413: 796.
21. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, et al. (2000) Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287: 1046-1049.
22. Alloatti G, Marcantoni A, Levi R, Gallo MP, Del Sorbo L, et al. (2005) Phosphoinositide 3-kinase gamma controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. FEBS Lett 579: 133-140.
23. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, et al. (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118: 375-387.
24. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, et al. (1995) Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269: 690-693.
25. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, et al. (2005) The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 106: 150-157.
26. Li LX, MacDonald PE, Ahn DS, Oudit GY, Backx PH, et al. (2006) Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. Endocrinology 147: 3318-3325.
27. MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, et al. (2004) Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase. Endocrinology 145: 4078-4083.
28. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, et al. (2005) Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 201: 1217-1228.
29. Pankow S, Bamberger C, Klippel A, Werner S (2006) Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J Cell Sci 119: 4033-4046.
30. Ito Y, Sakagami H, Kondo H (1996) Enhanced gene expression for phosphatidylinositol 3-kinase in the hypoglossal motoneurons following axonal crush. Brain Res Mol Brain Res 37: 329-332.
31. Okamoto T, Namikawa K, Asano T, Takaoka K, Kiyama H (2004) Differential regulation of the regulatory subunits for phosphatidylinositol 3-kinase in response to motor nerve injury. Brain Res Mol Brain Res 131: 119-125.
32. Northcott CA, Hayflick J, Watts SW (2005) Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility. Clinical and Experimental Pharmacology and Physiology 32: 851-858.
33. Northcott CA, Hayflick JS, Watts SW (2004) PI3-Kinase Upregulation and Involvement in Spontaneous Tone in Arteries From DOCA-Salt Rats: Is p110{delta} the Culprit? Hypertension 43: 885-890.
34. Northcott CA, Poy MN, Najjar SM, Watts SW (2002) Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 91: 360-369.
35. Andreelli F, Laville M, Ducluzeau PH, Vega N, Vallier P, et al. (1999) Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42: 358-364.
36. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, et al. (2004) Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145: 1144-1150.
37. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, et al. (2001) Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50: 1134-1142.
38. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, et al. (1996) Acute Regulation by Insulin of Phosphatidylinositol-3-kinase, Rad, Glut 4, and Lipoprotein Lipase mRNA Levels in Human Muscle. J Clin Invest 98: 43-49.
39. Lefai E, Roques M, Vega N, Laville M, Vidal H (2001) Expression of the splice variants of the p85alpha regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients. Biochem J 360: 117-126.
40. Abell K, Bilancio A, Clarkson RWE, Tiffen PG, Altaparmakov AI, et al. (2005) Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 7: 392-398.
41. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, et al. (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol 87: 2859-2867.
42. Kallin A, Johannessen LE, Cani PD, Marbehant CY, Essaghir A, et al. (2007) SREBP1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55gamma. J Lipid Res. M700136-JLR700200.
43. Park SY, Lee JH, Ha M, Nam JW, Kim VN (2008) miR-29 miRNAs activate p53 by targeting p85alpha and CDC42. Nat Struct Mol Biol.
44. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, et al. (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer.
45. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, et al. (2008) Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 121: 664-674.
46. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, et al. (2008) The forkhead transcription factor FOXO3a increases PI3K/Akt activity in drug-resistant leukaemic cells through induction of PIK3CA expression. Mol Cell Biol.
47. Yang N, Huang J, Greshock J, Liang S, Barchetti A, et al. (2008) Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS ONE 3: e1758.
48. Baier R, Bondeva T, Klinger R, Bondev A, Wetzker R (1999) Retinoic acid induces selective expression of phosphoinositide 3-kinase gamma in myelomonocytic U937 cells. Cell Growth Differ 10: 447-456.
49. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A (2009) Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia Without Affecting Atra-Induced Differentiation. Cancer Res 69: 1027-1036.
50. Geiman TM, Robertson KD (2002) Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem 87: 117-125.
51. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074-1080.
52. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G (1999) The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 274: 32091-32098.
53. Shestakova E, Bandu MT, Doly J, Bonnefoy E (2001) Inhibition of histone deacetylation induces constitutive derepression of the beta interferon promoter and confers antiviral activity. J Virol 75: 3444-3452.
54. Clayton E, McAdam S, Coadwell J, Chantry D, Turner M (2001) Structural organization of the mouse phosphatidylinositol 3-kinase p110d gene. Biochem Biophys Res Commun 280: 1328-1332.
55. Buratowski S (2008) Transcription. Gene expression-where to start? Science 322: 1804-1805.
56. Core LJ, Waterfall JJ, Lis JT (2008) Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322: 1845-1848.
57. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW (2008) The antisense transcriptomes of human cells. Science 322: 1855-1857.
58. Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, et al. (2008) RNA exosome depletion reveals transcription upstream of active human promoters. Science 322: 1851-1854.
59. Seila AC, Calabrese JM, Levine SS, Yeo GW, Rahl PB, et al. (2008) Divergent transcription from active promoters. Science 322: 1849-1851.
60. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
61. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, et al. (1998) Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood 91: 419-430.
62. Bories JC, Willerford DM, Grevin D, Davidson L, Camus A, et al. (1995) Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377: 635-638.
63. Hart A, Melet F, Grossfeld P, Chien K, Jones C, et al. (2000) Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13: 167-177.
64. Iwama A, Zhang P, Darlington GJ, McKercher SR, Maki R, et al. (1998) Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. Nucleic Acids Res 26: 3034-3043.
65. Muthusamy N, Barton K, Leiden JM (1995) Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature 377: 639-642.
66. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, et al. (1997) PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 6: 437-447.
67. Su GH, Chen HM, Muthusamy N, Garrett-Sinha LA, Baunoch D, et al. (1997) Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J 16: 7118-7129.
68. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, et al. (1997) Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J 16: 4374-4383.
69. Ozato K, Tailor P, Kubota T (2007) The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 282: 20065-20069.
70. Paun A, Pitha PM (2007) The IRF family, revisited. Biochimie 89: 744-753.
71. Rao A (1994) NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today 15: 274-281.
72. De Boer ML, Mordvinov VA, Thomas MA, Sanderson CJ (1999) Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoetic cells. Int J Biochem Cell Biol 31: 1221-1236.
73. Travis A, Amsterdam A, Belanger C, Grosschedl R (1991) LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev 5: 880-894.
74. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.
75. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. (1992) RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68: 855-867.
76. Jin ZX, Kishi H, Wei XC, Matsuda T, Saito S, et al. (2002) Lymphoid enhancer-binding factor-1 binds and activates the recombination-activating gene-2 promoter together with c-Myb and Pax-5 in immature B cells. J Immunol 169: 3783-3792.
77. Brickner AG, Gossage DL, Dusing MR, Wiginton DA (1995) Identification of a murine homolog of the human adenosine deaminase thymic enhancer. Gene 167: 261-266.
78. Sawada S, Littman DR (1991) Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene. Mol Cell Biol 11: 5506-5515.
79. Leiden JM, Thompson CB (1994) Transcriptional regulation of T-cell genes during T-cell development. Curr Opin Immunol 6: 231-237.
80. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, et al. (2006) Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A 103: 3799-3804.
81. Gebeshuber CA, Sladecek S, Grunert S (2007) Beta-catenin/LEF-1 signalling in breast cancer-central players activated by a plethora of inputs. Cells Tissues Organs 185: 51-60.
82. Hatsell S, Rowlands T, Hiremath M, Cowin P (2003) Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8: 145-158.
83. Ravindranath A, O'Connell A, Johnston PG, El-Tanani MK (2008) The role of LEF/TCF factors in neoplastic transformation. Curr Mol Med 8: 38-50.
84. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, et al. (2002) Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21: 8506-8509.
85. Furlan A, Vercamer C, Desbiens X, Pourtier A (2008) Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol 215: 782-793.
86. Buggy Y, Maguire TM, McDermott E, Hill AD, O'Higgins N, et al. (2006) Ets2 transcription factor in normal and neoplastic human breast tissue. Eur J Cancer 42: 485-491.
87. Zhang H, Xie X, Zhu X, Zhu J, Hao C, et al. (2005) Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem 280: 43188-43197.
88. Teschendorff AE, Journee M, Absil PA, Sepulchre R, Caldas C (2007) Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol 3: e161.
89. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034.
90. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, et al. (2003) The UCSC Genome Browser Database. Nucleic Acids Res 31: 51-54.
91. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, et al. (2004) Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 14: 708-715.
92. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
93. Down TA, Hubbard TJ (2002) Computational detection and location of transcription start sites in mammalian genomic DNA. Genome Res 12: 458-461.
94. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, et al. (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 15: 1034-1050.